Revance Therapeutics, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
32.75
|
|
Average Rating
|
4.08
|
|
# Strong Buys
|
5
|
|
# Buys
|
5
|
|
# Holds
|
2
|
|
# Sells
|
1
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.89
|
-1.17
|
-0.28
|
-31.46%
|
|
2022-06-30
|
-0.86
|
-0.88
|
-0.02
|
-2.33%
|
|
2022-03-31
|
-0.83
|
-0.94
|
-0.11
|
-13.25%
|
|
2021-12-31
|
-1.00
|
-0.93
|
0.07
|
7.00%
|
|
2021-09-30
|
-1.15
|
-1.10
|
0.05
|
4.35%
|
|
2021-06-30
|
-1.05
|
-1.07
|
-0.02
|
-1.90%
|
|
2021-03-31
|
-1.09
|
-1.08
|
0.01
|
0.92%
|
|
2020-12-31
|
-1.24
|
-1.24
|
0.00
|
0.00%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-2.99
|
|
2021-12-31
|
-4.18
|
|
2020-12-31
|
-4.85
|
|
2019-12-31
|
-3.66
|
|
2018-12-31
|
-3.94
|
|
2017-12-31
|
-3.99
|
|
2016-12-31
|
-3.18
|
|
2015-12-31
|
-3.00
|
|
2014-12-31
|
-3.71
|
|
2013-12-31
|
-0.02
|